midazolam and monomethyl auristatin e

midazolam has been researched along with monomethyl auristatin e in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Alley, SC; Chen, R; Cooper, M; Gopal, AK; Goy, A; Grove, LE; Han, TH; Lynch, CM; Matous, JV; O'Connor, OA; Ramchandren, R	1
Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H	1
Chen, Y; Ding, H; Girish, S; Jin, J; Li, C; Lu, D; Ma, F; Mao, J; Miles, D; Samineni, D; Shi, R; Wright, M	1

Trials

1 trial(s) available for midazolam and monomethyl auristatin e

Article	Year
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. Journal of clinical pharmacology, 2013, Volume: 53, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Feces; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Ketoconazole; Ki-1 Antigen; Male; Midazolam; Middle Aged; Oligopeptides; Rifampin; Young Adult	2013

Article

Year

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Journal of clinical pharmacology, 2013, Volume: 53, Issue:8

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Feces; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Ketoconazole; Ki-1 Antigen; Male; Midazolam; Middle Aged; Oligopeptides; Rifampin; Young Adult

2013

Other Studies

2 other study(ies) available for midazolam and monomethyl auristatin e

Article	Year
Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. Clinical pharmacokinetics, 2015, Volume: 54, Issue:1 Topics: Brentuximab Vedotin; Computer Simulation; Drug Interactions; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin	2015
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials. Journal of clinical pharmacology, 2020, Volume: 60 Suppl 1 Topics: Antibodies, Monoclonal; Brentuximab Vedotin; Computer Simulation; Cytochrome P-450 CYP3A; Drug Development; Drug Interactions; Drug Labeling; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin	2020

Article

Year

Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.

Clinical pharmacokinetics, 2015, Volume: 54, Issue:1

Topics: Brentuximab Vedotin; Computer Simulation; Drug Interactions; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin

2015

Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.

Journal of clinical pharmacology, 2020, Volume: 60 Suppl 1

Topics: Antibodies, Monoclonal; Brentuximab Vedotin; Computer Simulation; Cytochrome P-450 CYP3A; Drug Development; Drug Interactions; Drug Labeling; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin

2020